Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer

Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR mutation. To overcome this problem, we analysed the me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Discov
Main Authors: Li, Hongde, Stokes, William, Chater, Emily, Roy, Rajat, de Bruin, Elza, Hu, Yili, Liu, Zhigang, Smit, Egbert F, Heynen, Guus JJE, Downward, Julian, Seckl, Michael J, Wang, Yulan, Tang, Huiru, Pardo, Olivier E
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5037574/
https://ncbi.nlm.nih.gov/pubmed/27721983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/celldisc.2016.31
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados